Stock Scorecard



Stock Summary for Applied Dna Sciences Inc (APDN) - $5.62 as of 10/7/2025 5:28:04 PM EST

Total Score

13 out of 30

Safety Score

37 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for APDN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for APDN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for APDN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for APDN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for APDN (37 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for APDN

Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket - Applied DNA Sciences ( NASDAQ:APDN ) , Artelo Biosciences ( NASDAQ:ARTL ) 9/30/2025 9:37:00 AM
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Argo Blockchain ( NASDAQ:ARBK ) , Applied DNA Sciences ( NASDAQ:APDN ) 7/1/2025 9:23:00 AM
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August 6/16/2025 1:00:00 PM
Why Applied DNA Sciences ( APDN ) Stock Is Rising - Applied DNA Sciences ( NASDAQ:APDN ) 4/1/2025 4:05:00 PM
Applied DNA Sciences ( APDN ) Reports Q1 Loss, Tops Revenue Estimates 2/13/2025 10:20:00 PM
Why US Futures Are Rising Wednesday - Corvus Pharma ( NASDAQ:CRVS ) , Applied DNA Sciences ( NASDAQ:APDN ) 12/18/2024 11:22:00 AM
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket - AuthID ( NASDAQ:AUID ) , Applied DNA Sciences ( NASDAQ:APDN ) 12/18/2024 9:34:00 AM
General Mills, Micron Technology And 3 Stocks To Watch Heading Into Wednesday - General Mills ( NYSE:GIS ) , Applied DNA Sciences ( NASDAQ:APDN ) 12/18/2024 6:24:00 AM
Applied DNA Sciences ( APDN ) Reports Q4 Loss, Tops Revenue Estimates 12/17/2024 10:15:00 PM
Intellicheck Mobilisa, Inc. ( IDN ) Reports Q3 Loss, Misses Revenue Estimates 11/13/2024 10:30:00 PM

Financial Details for APDN

Company Overview

Ticker APDN
Company Name Applied Dna Sciences Inc
Country USA
Description Applied DNA Sciences, Inc. is a leading provider of DNA-based technology solutions, specializing in applications for pre-clinical drug development and manufacturing, as well as supply chain security, anti-counterfeiting, and anti-theft technologies. With a strong market presence across the United States, Europe, and Asia, the company leverages its innovative nucleic acid-based in vitro diagnostic technologies to address critical challenges in various industries. Headquartered in Stony Brook, New York, Applied DNA is positioned at the intersection of biotechnology and security, offering unique solutions that enhance product integrity and safety.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 6/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 5.62
Price 4 Years Ago 60,300.00
Last Day Price Updated 10/7/2025 5:28:04 PM EST
Last Day Volume 2,879,481
Average Daily Volume 835,062
52-Week High 319.95
52-Week Low 2.13
Last Price to 52 Week Low 163.85%

Valuation Measures

Trailing PE N/A
Industry PE 42.41
Sector PE 41.70
5-Year Average PE -16,540.94
Free Cash Flow Ratio 1.54
Industry Free Cash Flow Ratio 86.67
Sector Free Cash Flow Ratio 30.25
Current Ratio Most Recent Quarter 2.76
Total Cash Per Share 3.66
Book Value Per Share Most Recent Quarter 8.06
Price to Book Ratio 0.73
Industry Price to Book Ratio 244.81
Sector Price to Book Ratio 32.02
Price to Sales Ratio Twelve Trailing Months 1.94
Industry Price to Sales Ratio Twelve Trailing Months 4.67
Sector Price to Sales Ratio Twelve Trailing Months 20.22
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 1,291,500
Market Capitalization 7,258,230
Institutional Ownership 6.92%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.22%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 29.70%
Reported EPS 12 Trailing Months -57.12
Reported EPS Past Year -49.36
Reported EPS Prior Year -5.24
Net Income Twelve Trailing Months -37,105,122
Net Income Past Year -6,992,521
Net Income Prior Year -9,947,059
Quarterly Revenue Growth YOY -35.60%
5-Year Revenue Growth -8.63%
Operating Margin Twelve Trailing Months -1,214.00%

Balance Sheet

Total Cash Most Recent Quarter 4,727,677
Total Cash Past Year 6,431,095
Total Cash Prior Year 7,151,800
Net Cash Position Most Recent Quarter 4,727,677
Net Cash Position Past Year 6,431,095
Long Term Debt Past Year 0
Long Term Debt Prior Year 2,345,903
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 9,142,617
Total Stockholder Equity Prior Year 4,951,159
Total Stockholder Equity Most Recent Quarter 7,262,568

Free Cash Flow

Free Cash Flow Twelve Trailing Months -13,260,803
Free Cash Flow Per Share Twelve Trailing Months -10.27
Free Cash Flow Past Year -14,119,301
Free Cash Flow Prior Year -6,296,125

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.23
MACD Signal 0.00
20-Day Bollinger Lower Band -0.90
20-Day Bollinger Middle Band 4.33
20-Day Bollinger Upper Band 9.57
Beta 0.13
RSI 69.67
50-Day SMA 8,157.02
150-Day SMA 0.00
200-Day SMA 14,813.73

System

Modified 10/7/2025 5:28:06 PM EST